Sandeep Nayak
Physician-Scientist
Data updated
Research Footprint
Sandeep Nayak appears in 30 tracked papers (2020–2026) and 2 clinical trials, most studied alongside Psilocybin, DMT and LSD, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).
Most-cited paper: Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy (145 citations).
Frequent co-authors: David Yaden, Albert Garcia-Romeu and Roland Griffiths.
Publication Landscape
How the 30 papers Blossom tracks for Sandeep Nayak line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Sandeep Nayak's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 30 of 30 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Sandeep Nayak publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Sandeep Nayak publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Sandeep Nayak, MD, is a physician‑scientist affiliated with Johns Hopkins whose research focuses on the clinical, cognitive and safety consequences of classic psychedelics in both naturalistic and research settings. He has led and co‑authored prospective longitudinal work examining how psilocybin experiences alter mind perception and related belief systems, and has contributed to multiple analyses that probe drug–drug interactions and adverse events (for example, attenuation of psilocybin effects associated with SSRI/SNRI exposure and seizure risk signals when classic psychedelics are co‑administered with lithium). His publications also include comparative investigations of psychedelic and non‑ordinary experiences (such as near‑death experiences) and analyses of single transformative psychedelic experiences and their effects on attribution of consciousness to living and non‑living entities.
Beyond substantive clinical studies, Nayak has emphasised methodological rigour in psychedelic science — advocating for improved adverse‑event surveillance, reducing reporting bias and applying Bayesian approaches to trial design and analysis. He collaborates with neuroimaging groups and multidisciplinary teams to link phenomenology, safety, and neural measures, aiming to translate observational and experimental findings into safer, better‑characterised interventions for psychiatric care.
Key Impact
Known for empirical and methodological work on psychedelic-induced belief change, naturalistic psilocybin outcomes, and safety signals from drug co‑administration that inform clinical practice and trial design.
Collaboration Network
35 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Sandeep Nayak's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Sandeep Nayak is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →